Sientra Inc  

(Public, NASDAQ:SIEN)   Watch this stock  
Find more results for D. Scott Nugent
+0.10 (0.59%)
Apr 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.81 - 17.32
52 week 12.53 - 20.93
Open 17.06
Vol / Avg. 12,236.00/27,731.00
Mkt cap 251.78M
P/E     -
Div/yield     -
EPS -7.23
Shares 14.92M
Beta     -
Inst. own 97%
Mar 11, 2015
Q4 2014 Sientra Inc Earnings Call - Webcast
Mar 11, 2015
Q4 2014 Sientra Inc Earnings Release
Feb 11, 2015
Sientra Inc at 2015 Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -26.39% -12.99%
Operating margin -20.20% -12.93%
EBITD margin - -12.32%
Return on average assets -12.74% -6.05%
Return on average equity - -
Employees 95 -
CDP Score - -


420 S Fairview Ave Ste 200
SANTA BARBARA, CA 93117-3654
United States - Map
+1-805-5623500 (Phone)
+1-805-5628401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sientra, Inc. is a medical aesthetics company. The Company sells breast implants and breast tissue expanders or Breast Products to plastic surgeons. The Company�s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. The Company offers its products in over 120 variations of shapes, sizes and textures. Its breast implants are approved by the United States Food and Drug Administration (FDA). The Company�s product line includes Breast implants, Breast tissue expanders, Additional Tissue Expanders, Body Contouring, Facial Implants and Med Gel Accessories. The Company offers a range of breast implants, including anatomically-shaped textured, round textured and round smooth. The Company offers a line of breast tissue expanders, most of which are marketed as ACX, in 25 different shapes and sizes that include single and double chamber tissue expanders.

Officers and directors

Nicholas J. Simon III Independent Chairman of the Board
Bio & Compensation  - Reuters
Hani Zeini President, Chief Executive Officer, Founder, Director
Bio & Compensation  - Reuters
Matthew Pigeon Chief Financial Officer, Treasurer
Age: 46
Bio & Compensation  - Reuters
Joel Smith Chief Compliance Officer, General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Rosalyn D'Incelli Vice President, Clinical Operations
Bio & Compensation  - Reuters
JoAnn Kuhne Vice President - Regulatory Affairs & Quality Assurance
Bio & Compensation  - Reuters
Charles Huiner Chief Strategy and Corporate Development Officer
Age: 43
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 55
Bio & Compensation  - Reuters
Rishi Gupta Independent Director
Age: 37
Bio & Compensation  - Reuters
Timothy Haines Independent Director
Age: 56
Bio & Compensation  - Reuters